Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761994 | 0.78 | ADORA3 (0.40) | NPC1RAB9ATSHRKDM4EALDH1A1 | |
| SCHEMBL5759414 | 0.76 | ALDH1A1 (0.42) | CYP2D6POLBNPC1RAB9AKDM4E | |
| SCHEMBL5761635 | 0.76 | NTRK1 (0.33) | CYP2D6HRH1 | |
| SCHEMBL5759004 | 0.73 | PDE10A (0.33) | RAB9ATSHRNPSR1RXFP1 | |
| SCHEMBL5757427 | 0.73 | GABRA1 (0.36) | CYP2D6HRH1TSHRKDM4EALDH1A1 | |
| SCHEMBL5757777 | 0.72 | ALOX15 (0.40) | POLBNPC1RAB9ATSHRKDM4E | |
| SCHEMBL10832864 | 0.71 | SLC9A1 (0.37) | CYP2D6POLBNPC1RAB9ATSHR | |
| SCHEMBL909189 | 0.68 | TSHR (0.31) | POLBTSHRNPSR1RXFP1 | |
| SCHEMBL9372396 | 0.67 | SLC9A1 (0.40) | NPC1RAB9ATSHRKDM4EALDH1A1 | |
| SCHEMBL22833014 | 0.66 | MEN1 (0.48) | POLBRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1104403-B1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PROD INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050215549-A1 | TACE inhibitors | MCCLURE KIM F | 2005-09-29 | — | — | US | disclosed |
| EP-1104412-B1 | TACE INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20030181441-A1 | TACE INHIBITORS | McCLURE Kim (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MCCLURE KIM F (US) | 2003-01-09 | — | — | US | disclosed |
| US-6329397-B1 | TREATMENT OF A CONDITION SELECTED FROM THE GROUP CONSISTING OF ARTHRITIS, CANCER, AND OTHER DISEASES CHARACTERIZED BY MATRIX METALLOPROTEINASE OR MAMMALIAN REPROLYSIN ACTIVITY. | PFIZER | 2001-12-11 | — | — | US | disclosed |
| EP-1104412-A1 | TACE INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009492-A1 | TACE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181441-A1 | TACE INHIBITORS | ADAMTS5, ADAMTS1, MMP2 | CYP2D6 676/4885HRH1 1084/4885POLB 710/4885 |
| US-20050215549-A1 | TACE inhibitors | ADAMTS5, ADAMTS1, MMP2 | CYP2D6 851/4885HRH1 713/4885POLB 769/4885 |
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MMP1, MMP10, MMP3 | CYP2D6 2673/4885HRH1 222/4885POLB 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.